Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer

Xu, Tongpeng; Liu, X.; Han, Lei; Shen, Hong; Liu, L.; Shu, Yongqian

doi:10.1007/s12094-013-1106-1

Cited by 63 publications

(64 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, the study was conducted based on the available patient samples from both lung squamous cell carcinoma and lung adenocarcinoma and elucidated critical regulatory mechanisms for NSCLC. While we pointed this out as a limitation, several studies regarded these two subtypes together in order to infer critical biomolecules that have potential implications for the pathology of NSCLC (Raponi et al 2006;Ma et al 2011;Xu et al 2014). For example, after analyzing 116 tumor samples (69 squamous cell carcinoma and 47 adenocarcinoma) and adjacent normal lung tissue samples, Xu et al (2014) demonstrated that high miR-9-5p expression is associated with poorer progression-free survival (P-value < 10…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, TGFBR2 was reported as a direct target of miR-17-5p (Dews et al 2010). So far, the expression pattern for miR-9-5p in lung tumor versus non-tumor samples has been inconsistently reported: up-regulation (Crawford et al 2009;Kang et al 2013;Xu et al 2014), downregulation (Yanaihara et al 2006), or insignificant change in expression (Jusufovic et al 2012). To the best of our knowledge, there is no report on miR-130b-3p expression in NSCLC.…”

Section: Systematic Filtering Of Critical Mirnas In Nsclcmentioning

confidence: 97%

See 1 more Smart Citation

Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer

Mitra

Edmonds

Sun

et al. 2014

RNA

View full text Add to dashboard Cite

While previous studies reported aberrant expression of microRNAs (miRNAs) in non-small cell lung cancer (NSCLC), little is known about which miRNAs play central roles in NSCLC's pathogenesis and its regulatory mechanisms. To address this issue, we presented a robust computational framework that integrated matched miRNA and mRNA expression profiles in NSCLC using feed-forward loops. The network consists of miRNAs, transcription factors (TFs), and their common predicted target genes. To discern the biological meaning of their associations, we introduced the direction of regulation. A network edge validation strategy using three independent NSCLC expression profiling data sets pinpointed reproducible biological regulations. Reproducible regulation, which may reflect the true molecular interaction, has not been applied to miRNA-TF coregulatory network analyses in cancer or other diseases yet. We revealed eight hub miRNAs that connected to a higher proportion of targets validated by independent data sets. Network analyses showed that these miRNAs might have strong oncogenic characteristics. Furthermore, we identified a novel miRNA-TF co-regulatory module that potentially suppresses the tumor suppressor activity of the TGF-β pathway by targeting a core pathway molecule (TGFBR2). Follow-up experiments showed two miRNAs (miR-9-5p and miR-130b-3p) in this module had increased expression while their target gene TGFBR2 had decreased expression in a cohort of human NSCLC. Moreover, we demonstrated these two miRNAs directly bind to the 3 ′ untranslated region of TGFBR2. This study enhanced our understanding of miRNA-TF co-regulatory mechanisms in NSCLC. The combined bioinformatics and validation approach we described can be applied to study other types of diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Systematic Filtering Of Critical Mirnas In Nsclcmentioning

confidence: 97%

Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer

Mitra

Edmonds

Sun

et al. 2014

RNA

View full text Add to dashboard Cite

show abstract

“…[8][9][10] MiRNAs are present in a stable form in human serum and plasma, suggesting the potential use of circulating miRNAs as stable blood-based markers for the detection of cancer or other human diseases. [11][12][13] MicroRNA-9 is upregulated in many tumour types including colorectal, 14 breast 15 and non-small cell lung cancer, 16 but its role in the progression of osteosarcoma remains unknown. The aim of this study, therefore, was to analyse the association between serum miR-9 concentrations and clinicopathological features and prognosis, in patients with osteosarcoma.…”

Section: Introductionmentioning

confidence: 99%

Serum miR-9 as a prognostic biomarker in patients with osteosarcoma

et al. 2014

View full text Add to dashboard Cite

Objectives: To quantify microRNA-9 (miR-9) concentrations in the serum of patients with osteosarcoma; to explore its relationship with clinicopathological characteristics and prognosis of osteosarcoma. Method: Serum miR-9 was quantified via real-time reverse transcription-polymerase chain reaction in patients with osteosarcoma and healthy control subjects. Overall survival was evaluated using the Kaplan-Meier method. Results: Serum miR-9 was significantly upregulated in patients with osteosarcoma (n ¼ 118) compared with healthy control subjects (n ¼ 60); its upregulation was significantly associated with advanced tumour-node-metastasis stage, larger tumour size and presence of distant metastasis. Overall survival duration was significantly shorter in patients with relatively high miR-9 concentrations compared with those with relatively low miR-9 concentrations. Conclusions: Serum miR-9 concentrations are significantly increased in patients with osteosarcoma compared with healthy controls. Upregulation of miR-9 is associated with tumour stage, size and metastasis. Serum miR-9 quantification may represent a useful diagnostic and prognostic marker of osteosarcoma.

show abstract

“…Functional studies performed in cancer ce ll lines or animal models of various cancers suggest that, miRNAs can function as tumor suppressors, oncogenes, and regulate cancer pathways (Farazi et al, 2011). Aberrant expression of specific miRNAs has been reported in many tumor types 1 such as CRC, breast cancer, cervical cancer, non-small cell lung cancer, ovarian cancer and bladder cancer as well as being associated with patients' survival data, metastasis, and other clinicopathological factors (Toyama et al, 2012;Wan et al, 2012;Shen et al, 2013;Wang et al, 2013;Xiao et al, 2013;Liu et al, 2014;Xu et al, 2014). A previous study showed that miR-32 expression was upregulated in CRC tissues, and high expression was significantly correlated with the tumor stage, distal metastases and poor prognoses (Wu et al, 2013b).…”

Section: Introductionmentioning

confidence: 99%

Expression and Clinical Significance of MicroRNA-376a in Colorectal Cancer

Wu²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The incidence of colorectal cancer (CRC) is increasing in many Asian countries and microRNAs have already been proven to be associated with tumorigenesis. Currently, microRNA-376a (miR-376a) expression and association with clinical factors in CRC remains unclear. In this study, real-time quantitative reverse transcriptasepolymerase chain reaction (qRT-PCR) was carried out on 53 matched pairs of CRC and adjacent normal mucosa to investigate the expression levels of miR-376a. According to the high or low expression of miR-376a, patients were divided into two groups. The relationship between miR-376a expression and clinicopathological factors of 53 patients was evaluated. Survival analysis of 53 CRC patients was performed with clinical followup information and survival curves were assessed by the Kaplan-Meier method. Immunohistochemistry (IHC) staining was performed on sections of paraffin-embedded tissue to investigate the vascular endothelial growth factor (VEGF) expression. MiR-376a showed low expression in cancer tissues compared to the adjacent normal tissues and altered high miR-376a expression tended to be positively correlated with advanced lymph node metastasis and shorter patient survival. VEGF IHC positivity was significantly more common in patients with high expression levels of miR-376a.Those results demonstrated that miR-376a may be a meaningful prognostic biomarker and potential therapeutic target in colorectal cancer.

show abstract

Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer

Cited by 63 publications

References 30 publications

Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer

Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer

Serum miR-9 as a prognostic biomarker in patients with osteosarcoma

Expression and Clinical Significance of MicroRNA-376a in Colorectal Cancer

Contact Info

Product

Resources

About